Sawabu Tateo, Seno Hiroshi, Kawashima Tomoko, Fukuda Akihisa, Uenoyama Yoshito, Kawada Mayumi, Kanda Naoki, Sekikawa Akira, Fukui Hirokazu, Yanagita Motoko, Yoshibayashi Hiroshi, Satoh Seiji, Sakai Yoshiharu, Nakano Toru, Chiba Tsutomu
Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Mol Carcinog. 2007 Feb;46(2):155-64. doi: 10.1002/mc.20211.
Activation of tyrosine kinases is an important factor during cancer development. Axl, one of the receptor tyrosine kinases, binds to the specific ligand growth arrest-specific gene 6 (Gas6), which encodes a vitamin K-dependent gamma-carboxyglutamyl protein. Although many receptor tyrosine kinases and their ligands are involved in gastric carcinogenesis, whether Gas6-Axl signaling is involved in gastric carcinogenesis has not been elucidated. The aim of this study was to investigate the expression of Gas6 and Axl in gastric cancer and also their roles during gastric carcinogenesis. mRNA and protein of Gas6 and Axl were highly expressed in a substantial proportion of human gastric cancer tissue and cell lines, and Gas6 expression was significantly associated with lymph node metastasis. With recombinant Gas6 and a decoy-receptor of Axl in vitro, we demonstrated that Gas6-Axl signaling pathway enhanced cellular survival and invasion and suppressed apoptosis via Akt pathway. Our results suggests that Gas6-Axl signaling plays a role during gastric carcinogenesis, and that targeting Gas6-Axl signaling could be a novel therapeutic for gastric cancer.
酪氨酸激酶的激活是癌症发展过程中的一个重要因素。受体酪氨酸激酶之一的Axl与特异性配体生长停滞特异性基因6(Gas6)结合,Gas6编码一种维生素K依赖性γ-羧基谷氨酸蛋白。尽管许多受体酪氨酸激酶及其配体参与胃癌发生,但Gas6-Axl信号通路是否参与胃癌发生尚未阐明。本研究的目的是调查Gas6和Axl在胃癌中的表达及其在胃癌发生过程中的作用。Gas6和Axl的mRNA及蛋白在相当一部分人胃癌组织和细胞系中高表达,且Gas6表达与淋巴结转移显著相关。在体外利用重组Gas6和Axl的诱饵受体,我们证明Gas6-Axl信号通路通过Akt途径增强细胞存活和侵袭并抑制细胞凋亡。我们的结果表明Gas6-Axl信号通路在胃癌发生过程中发挥作用,靶向Gas6-Axl信号通路可能是一种新型的胃癌治疗方法。
J Cell Physiol. 2005-7
Biochem Biophys Res Commun. 2004-7-2
PLoS One. 2009-10-30
Curr Issues Mol Biol. 2024-10-13
Nat Rev Clin Oncol. 2023-11
Front Oncol. 2023-5-10
Front Immunol. 2021
Mol Med Rep. 2022-1